Sukumar Ranjith

Mr. Sukumar Ranjith

Department of Marine Biotechnology, Bharathidasan University, Tiruchchirappalli, India
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
SDSenbagam Duraisamy
Senbagam Duraisamy
SBSenthilkumar Balakrishnan
Senthilkumar Balakrishnan
SRSukumar Ranjith
Sukumar Ranjith
FHFazal Husain
Fazal Husain
ASAswathy Sathyan
Aswathy Sathyan
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy

10 January 2022 in Biologia
Verified
Journal Article
Closed access
PDF file
FHFazal Husain
Fazal Husain
SDSenbagam Duraisamy
Senbagam Duraisamy
SBSenthilkumar Balakrishnan
Senthilkumar Balakrishnan
SRSukumar Ranjith
Sukumar Ranjith
PCPrahalathan Chidambaram
Prahalathan Chidambaram
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy

26 January 2024 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
APAnsu Susan Peter
Ansu Susan Peter
ASAswathy Sathyan
Aswathy Sathyan
SRSukumar Ranjith
Sukumar Ranjith
IKIndira Kandasamy
Indira Kandasamy
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
The demand for massive quantities of therapeutic active antimicrobial peptides (AMPs) is high due to their potential as alternatives to antibiotics. However, each antimicrobial peptide has unique properties, necessitating distinct synthesis and purification strategies for their large-scale production. In this study, we bio-synthesized and purified a functional enhanced variant of the AMP epinecidin-1, known as Ac-Var-1 (acid-cleavable variant-1). To generate the active peptide, we cloned the gene for Ac-Var-1 with acid-cleavable site (aspartic acid-proline) into the pET-32a expression vector, purified the fusion protein by His tag enrichment chromatography, and performed acid cleavage to release the active Ac-Var-1 peptide. After acid cleavage, the active Ac-Var-1 was purified and characterized by SDS-PAGE and mass spectrometry. The results from both techniques provided confirmation of the intactness of the purified Ac-Var-1. The Ac-Var-1 inhibited the growth of pathogenic Escherichia coli and Staphylococcus aureus. Key points: • Epinecidin-1 is a well-known antimicrobial peptide having multipotential bioactivities. • Epinecidin-1 variant is developed via the site-directed mutagenesis method to improve its structural stability and bioactivity. • AC-Var-1 development is an economical and easy method to remove peptide from tag protein.

3 June 2023 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
ASAswathy Sathyan
Aswathy Sathyan
APAnsu Susan Peter
Ansu Susan Peter
SRSukumar Ranjith
Sukumar Ranjith
SDSenbagam Duraisamy
Senbagam Duraisamy
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy

12 December 2024 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
SRSukumar Ranjith
Sukumar Ranjith
RVRaja Veerapandian
Raja Veerapandian
KNKalimuthusamy Natarajaseenivasan
Kalimuthusamy Natarajaseenivasan
PCPrahalathan Chidambaram
Prahalathan Chidambaram
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy
Background/Objective: Indwelling intrauterine contraceptive devices (IUDs) have surfaces that facilitate the attachment of Candida spp., creating a suitable environment for biofilm formation. Due to this, vulvovaginal candidiasis (VVC) is frequently linked to IUD usage, necessitating the prompt removal of these devices for effective treatment. In this study, we evaluated the susceptibility of antimicrobial peptides in vitro against biofilm forming, Amphotericin B (MIC50 > 2 mg L−1) resistant Candida krusei and Candida tropicalis isolated from IUD users who had signs of vaginal candidiasis (hemorrhage, pelvic pain, inflammation, itching, and vaginal discharge). Three antimicrobial peptides, namely, epinecidin-1 (epi-1) and its two variants, namely, variant-1 (Var-1) and variant-2 (Var-2), which were reported to have enhanced antibacterial activity were tested against IUD isolates (C. krusei and C. tropicalis) with pathogenic form of Candida albicans as control. Variants of epi-1, namely, Var-1 and Var-2 were created by substituting lysine in the place of histidine and alanine. Methods: The antimicrobial activity was measured using the microbroth dilution method to determine the minimum inhibitory concentration (MIC) of peptides against C. albicans, C. krusei and C. tropicalis. The MIC of each peptide was used for biofilm assay by Crystal violet staining, Scanning Electron Microscopy, and Reactive Oxygen Species (ROS) assay. To find the possible mechanism of anti-biofilm activity by the peptides, their ability to interact with Candida spp. cell membrane proteins such as Exo-β-(1,3)-Glucanase, Secreted Aspartic Proteinase (Sap) 1, and N-terminal Domain Adhesin: Als 9-2 were determined through PatchDock. Results: The MIC values of peptides: epi-1, var-1 and var-2 against C. albicans are 128 μg mL−1, 64 μg mL−1 and 32 μg mL−1, C. tropicalis are 256 μg mL−1, 64 μg mL−1, and 32 μg mL−1 and C. krusei are 128 µg mL−1, 128 µg mL−1 and 64 µg mL−1, respectively. Both the variants outperformed epi-1. Specifically for tested Candida spp., var-1 showed two- to four-fold enhancements and var-2 showed two- to eight-fold enhancements compared to epi-1. Electron microscopy confirmed that the mechanism of action involves pore formation thus inducing reactive oxygen species in Candida spp. cell membrane. Computational analysis showed that the peptides have a high tendency to interact with Candida spp. cell membrane proteins such as Exo-β-(1,3)-Glucanase, Secreted Aspartic Proteinase (Sap) 1, and N-terminal Domain Adhesin: Als 9-2, thereby preventing biofilm formation. Conclusions: The in vitro evidence supports the potential use of epi-1 and its variants to be used as an anti-biofilm agent to coat IUDs in the future for therapeutic purposes.

21 July 2024 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
SJSivakumar Jeyarajan
Sivakumar Jeyarajan
APAnsu Susan Peter
Ansu Susan Peter
SRSukumar Ranjith
Sukumar Ranjith
ASAswathy Sathyan
Aswathy Sathyan
SDSenbagam Duraisamy
Senbagam Duraisamy
AKAnbarasu Kumarasamy
Anbarasu Kumarasamy